Literature DB >> 14734215

Performance characteristics of the IMMUNLITE 2000 erythropoietin assay.

William E Owen1, William L Roberts.   

Abstract

BACKGROUND: Erythropoietin (EPO) is a glycoprotein hormone produced by specialized cells in the kidney that acts as the primary regulator of erythropoiesis. Serum EPO measurements are useful for diagnostic evaluations of anemia and polycythemia.
METHODS: The IMMULITE 2000 is an automated random access immunoassay analyzer for the central laboratory. The limit of detection (LOD), linearity, imprecision, comparison to another commercially available assay, and reference interval of a new EPO assay for this analyzer were assessed.
RESULTS: The LOD was 0.2 U/l. The assay was linear within an allowable systematic error of 10% over the range tested (2-178 U/l). The total imprecision of the new assay was <7% for concentrations from 15.8 to 68.4 U/l. Comparison with the Advantage EPO assay method showed comparable results. Deming regression analysis gave a slope of 1.13+/-0.02, an intercept of -1.09+/-0.97, and a S(y/x) of 7.1 (r=0.99) over the range tested (2-200 U/l).
CONCLUSIONS: The IMMULITE 2000 EPO assay shows acceptable performance and is suitable for routine clinical use.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14734215     DOI: 10.1016/j.cccn.2003.11.005

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  3 in total

1.  A common, under-recognized cause of elevated serum erythropoietin.

Authors:  Daria V Babushok; David Cardamone; Nichole Rulander; Stephen R Master; Elizabeth O Hexner
Journal:  Am J Med       Date:  2014-08-19       Impact factor: 4.965

2.  Evaluation of a (1->3)-beta-D-glucan assay for diagnosis of invasive fungal infections.

Authors:  Jerry W Pickering; Howard W Sant; Catherine A P Bowles; William L Roberts; Gail L Woods
Journal:  J Clin Microbiol       Date:  2005-12       Impact factor: 5.948

3.  Aqueous levels of erythropoietin in acute retinal vein occlusion with macular edema.

Authors:  Hyun Jin Shin; Hyung Chan Kim; Jun Woong Moon
Journal:  Int J Ophthalmol       Date:  2014-06-18       Impact factor: 1.779

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.